Published in Antimicrob Agents Chemother on April 01, 1993
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A (1999) 1.65
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother (1994) 1.33
Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc Natl Acad Sci U S A (1997) 1.17
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother (1995) 1.13
Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease. Protein Sci (1999) 1.05
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. J Virol (1999) 0.98
Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother (1997) 0.97
Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother (1998) 0.94
Modeling Protein-Ligand Binding by Mining Minima. J Chem Theory Comput (2010) 0.92
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.87
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Antimicrob Agents Chemother (1997) 0.83
Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother (1999) 0.77
Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages. Antimicrob Agents Chemother (2002) 0.77
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Antimicrob Agents Chemother (1998) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A (1991) 5.83
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
The kinetics of reversible tight-binding inhibition. Methods Enzymol (1979) 4.13
HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science (1986) 3.06
Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology (1992) 2.88
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science (1991) 2.37
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1991) 2.16
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology (1993) 1.92
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med (1974) 1.48
Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci (1987) 1.23
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. J Med Chem (1990) 1.05
Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B. J Med Chem (1977) 1.01
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem (1991) 1.00
Renin inhibitors. Med Res Rev (1990) 0.98
Inhibitors of HIV-1 protease. J Enzyme Inhib (1992) 0.98
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1990) 0.97
Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem Pharm Bull (Tokyo) (1992) 0.93
Association of human lymph node homing receptor (Leu 8) with the TCR/CD3 complex. J Immunol (1992) 0.93
Absorption of cyclosporine A after oral dosing. Transplant Proc (1986) 0.92
New human renin inhibitors containing an unnatural amino acid, norstatine. J Med Chem (1988) 0.88
KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo) (1991) 0.86
Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo) (1991) 0.85
Efficient solid phase peptide synthesis. Use of methanesulfonic acid alpha-amino deprotecting procedure and new coupling reagent, 2-(benzotriazol-1-yl)oxy-1,3-dimethylimidazolidinium hexafluorophosphate (BOI). Int J Pept Protein Res (1993) 0.78
A uniquely potent renin inhibitor and its unanticipated plasma binding component. J Med Chem (1985) 0.78
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction. J Med Chem (1990) 0.78
Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet (2001) 18.55
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science (1990) 4.01
Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. Development (2000) 3.70
Clinical features and management of hepatic portal venous gas: four case reports and cumulative review of the literature. Arch Surg (2001) 3.66
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer (1984) 3.49
Prospective randomized pilot trial of selective biliary cannulation using pancreatic guide-wire placement. Endoscopy (2003) 3.24
New measurement system for fault location in optical waveguide devices based on an interferometric technique. Appl Opt (1987) 3.15
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A (1996) 3.07
The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem (1994) 3.06
TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem (1997) 3.03
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol (1994) 2.81
Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol (1999) 2.81
Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development (2000) 2.73
Finer features for functional microdevices. Nature (2001) 2.73
Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J Cell Biol (2001) 2.73
Calcium and potassium currents of the membrane of a barnacle muscle fibre in relation to the calcium spike. J Physiol (1969) 2.63
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol (1998) 2.61
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Ultrasound-guided infraclavicular brachial plexus block: an alternative technique to anatomical landmark-guided approaches. Reg Anesth Pain Med (2001) 2.53
Function and assembly of photosystem II: genetic and molecular analysis. Trends Biochem Sci (1988) 2.52
Complete nucleotide sequence of cDNA and predicted amino acid sequence of rat acyl-CoA oxidase. J Biol Chem (1987) 2.51
Changes in anterior chamber angle width and depth after intraocular lens implantation in eyes with glaucoma. Ophthalmology (2000) 2.48
Fragmin: a calcium ion sensitive regulatory factor on the formation of actin filaments. Biochemistry (1980) 2.48
Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet (1998) 2.44
Brain MR in Fukuyama congenital muscular dystrophy. AJNR Am J Neuroradiol (1996) 2.42
Anterior capsule contraction and intraocular lens dislocation after implant surgery in eyes with retinitis pigmentosa. Ophthalmology (1998) 2.37
Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med (1992) 2.30
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg (1998) 2.26
Calcium-regulated modulator protein interacting agents inhibit smooth muscle calcium-stimulated protein kinase and ATPase. Mol Pharmacol (1980) 2.18
Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver catalase. Proc Natl Acad Sci U S A (1986) 2.15
New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology (2005) 2.14
Transplantation of human tumors in nude mice. J Natl Cancer Inst (1976) 2.13
tRNA genes as transcriptional repressor elements. Mol Cell Biol (1994) 2.10
AmpG, a signal transducer in chromosomal beta-lactamase induction. Mol Microbiol (1993) 2.06
Heat shock regulatory gene rpoH mRNA level increases after heat shock in Escherichia coli. J Bacteriol (1986) 2.04
Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem Biophys Res Commun (1993) 2.03
Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation (1989) 2.03
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms. Circulation (1975) 1.98
New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase. J Biochem (1977) 1.96
Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins. Haemostasis (1978) 1.96
The virR gene, a member of a class of two-component response regulators, regulates the production of perfringolysin O, collagenase, and hemagglutinin in Clostridium perfringens. J Bacteriol (1994) 1.95
Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy (1998) 1.93
Another African disaster. BMJ (1992) 1.91
Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. Hypertension (1997) 1.90
Reduction in the area of the anterior capsule opening after polymethylmethacrylate, silicone, and soft acrylic intraocular lens implantation. Am J Ophthalmol (1997) 1.90
Risk factors for corneal endothelial injury during phacoemulsification. J Cataract Refract Surg (1996) 1.88
Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia. J Biol Chem (1998) 1.87
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol (1999) 1.86
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res (1987) 1.83
Immunoglobulin G as possible precursor of chemotactic factor. Nature (1970) 1.82
The virR/virS locus regulates the transcription of genes encoding extracellular toxin production in Clostridium perfringens. J Bacteriol (1996) 1.82
Adaptational change in proline and water content of Staphylococcus aureus after alteration of environmental salt concentration. Appl Environ Microbiol (1978) 1.81
Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J Virol (1996) 1.79
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol (1992) 1.77
Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol (1996) 1.77
Studies on bacterial chemotaxis. IV. Interaction of maltose receptor with a membrane-bound chemosensing component. J Biochem (1979) 1.76
Pre-steady-state kinetics of Escherichia coli aspartate aminotransferase catalyzed reactions and thermodynamic aspects of its substrate specificity. Biochemistry (1990) 1.76
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res (1999) 1.76
Occurrence of glucosamine residues with free amino groups in cell wall peptidoglycan from bacilli as a factor responsible for resistance to lysozyme. J Bacteriol (1973) 1.71
Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. J Virol (1997) 1.69
Studies on bacterial chemotaxis. II. Effect of cheB and cheZ mutations on the methylation of methyl-accepting chemotaxis protein of Escherichia coli. J Biochem (1979) 1.68
Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc Natl Acad Sci U S A (1993) 1.67
Effect of external and internal pH changes on K and Cl conductances in the muscle fiber membrane of a giant barnacle. J Gen Physiol (1968) 1.67
Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol (1998) 1.66
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J (2000) 1.66
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A (1999) 1.65
Amino-acid sequence of slightly lysine-rich histone. Nature (1970) 1.65
Reactive hemophagocytosis in systemic lupus erythematosus. Intern Med (1998) 1.65
Cross-linking of IgE-receptor complexes at the cell surface: a fluorescence method for studying the binding of monovalent and bivalent haptens to IgE. Mol Immunol (1986) 1.65
Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res (2001) 1.64
Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin. Eur J Biochem (1988) 1.62
Isolation and the gene cloning of an alkaline shock protein in methicillin resistant Staphylococcus aureus. Biochem Biophys Res Commun (1995) 1.60
Epstein-Barr virus-associated gastric carcinoma and atrophic gastritis. J Clin Gastroenterol (1999) 1.59
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res (1997) 1.58
The correlation between incision size and corneal shape changes in sutureless cataract surgery. Ophthalmology (1995) 1.57
Cloning and characterization of a chromosomal gene cluster, pah, that encodes the upper pathway for phenanthrene and naphthalene utilization by Pseudomonas putida OUS82. J Bacteriol (1994) 1.56
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis (1995) 1.56
Effect of cataract surgery on intraocular pressure control in glaucoma patients. J Cataract Refract Surg (2001) 1.56
Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. J Biol Chem (1995) 1.55
Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol (2001) 1.55
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol (1998) 1.55
Intraocular lens implantation in a child with monocular cataract and anterior persistent hyperplastic primary vitreous. J Cataract Refract Surg (2001) 1.54
Mechanisms of anion and cation permeations in the resting membrane of a barnacle muscle fiber. J Gen Physiol (1971) 1.54
Physiology and morphology of substantia gelatinosa neurons intracellularly stained with horseradish peroxidase. J Comp Neurol (1980) 1.53
Electrolyzed-reduced water scavenges active oxygen species and protects DNA from oxidative damage. Biochem Biophys Res Commun (1997) 1.53
OCAM: A new member of the neural cell adhesion molecule family related to zone-to-zone projection of olfactory and vomeronasal axons. J Neurosci (1997) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol (1999) 1.52
Direct demonstration of insulin-induced GLUT4 translocation to the surface of intact cells by insertion of a c-myc epitope into an exofacial GLUT4 domain. J Biol Chem (1993) 1.52
Corneal endothelial cell loss in phacoemulsification surgery with silicone intraocular lens implantation. J Cataract Refract Surg (1996) 1.52
Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J Interferon Cytokine Res (2000) 1.52
Alteration of the phospholipid composition of Staphylococcus aureus cultured in medium containing NaCl. Biochim Biophys Acta (1972) 1.52
Inhibition of cholesterol synthesis from mevalonate by aminotriazole treatment in vivo. Chem Pharm Bull (Tokyo) (1990) 1.51